Feed excerpt — reported by Inc.
Developed to treat erectile dysfunction, AR1001 slowed Alzheimer’s decline by 31 percent in one specific group. Researchers say the results represent an important milestone.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at Inc. →